ARWR vs DOCU · rev $829.4M vs P/E 15, rev $1.71B
Arrowhead Pharmaceuticals Inc (ARWR) versus DocuSign Inc (DOCU) — a side-by-side from cached financials, not a winner call.
Arrowhead Pharmaceuticals Inc (ARWR) is a biotechnology company listed on US.
DocuSign Inc (DOCU) is a software - application company listed on US.
Latest reported ARWR revenue for 2025-09-30 was $829.4M. Net income was $30.1M. Revenue was up 23258.2% from 2024-09-30 to 2025-09-30. ARWR currently screens at market cap $10.59B.
Latest reported DOCU revenue for 2026-07-31 was $1.71B. Net income was $155.9M. DOCU currently screens at market cap $15.74B and trailing P/E 14.8.
ARWR currently screens at market cap $10.59B. DOCU currently screens at market cap $15.74B and trailing P/E 14.8.
Not investment advice. Open the ARWR and DOCU stock pages for the full models.
Not investment advice.